|
Post by nylefty on Jun 4, 2019 19:05:40 GMT -5
They have to get the pricing approved first. "The commercialization of Afrezza in Brazil is expected to begin in the fourth quarter this year, subject to the pricing registration process by Câmara de Regulação do Mercado de Medicamentos (CMED). "In marketing, pricing is the last thing that goes into any plan. So? My point was that now that one Brazilian agency has approved Afrezza, another government agency has to approve its pricing. That will take a while, no matter what plan Mike & Co. came up with.
|
|
|
Post by radgray68 on Jun 4, 2019 21:17:52 GMT -5
If they are already on to pricing, that would say to me that management is on top of things. Not understanding the bashing of management for...succeeding in gaining approval. Reaching.
|
|
|
Post by theshiv on Jun 4, 2019 23:19:53 GMT -5
We should celebrate the Brazil approval as it is good news and we don't get to experience that everyday. It is a positive for the company and hopefully they will come through with additional early morning unexpected positive announcements as we move forward.
|
|
|
Post by mytakeonit on Jun 4, 2019 23:45:26 GMT -5
Oh No .. just got back from Japan and plan to buy more shares in the morning ... current pps is what I had expected, as previously stated. Will place a low ball order, but will adjust if things don't go my way.
Will be great if we all could meet in the future. (Hey sports ... my future wife!!! I'm talking to you !!!)
But, that's mytakeonit
|
|
|
Post by sportsrancho on Jun 5, 2019 7:17:23 GMT -5
Oh No .. just got back from Japan and plan to buy more shares in the morning ... current pps is what I had expected, as previously stated. Will place a low ball order, but will adjust if things don't go my way. Will be great if we all could meet in the future. (Hey sports ... my future wife!!! I'm talking to you !!!) But, that's mytakeonit “Have tent will follow”😁🌴 it’s getting really hot out here in California😎
|
|
|
Post by prcgorman2 on Jun 5, 2019 9:08:37 GMT -5
In marketing, pricing is the last thing that goes into any plan. So? My point was that now that one Brazilian agency has approved Afrezza, another government agency has to approve its pricing. That will take a while, no matter what plan Mike & Co. came up with. This is an interesting point in that a decision is to be made whether Afrezza will be included in the drug formulary of the national health plan or not. Last year MC downplayed Brazil (and India) with regard to making big bottom-line improvement impacts and pointed to the benefit of defrayed Afrezza manufacturing costs which seems to indicate he's not counting on national health plan adoption, but it is something to watch and hope for.
|
|
|
Post by boytroy88 on Jun 5, 2019 9:17:52 GMT -5
|
|
|
Post by harryx1 on Jun 5, 2019 9:19:14 GMT -5
|
|
|
Post by barnstormer on Jun 5, 2019 9:19:59 GMT -5
In marketing, pricing is the last thing that goes into any plan. So? My point was that now that one Brazilian agency has approved Afrezza, another government agency has to approve its pricing. That will take a while, no matter what plan Mike & Co. came up with. Will take a while? If Mike and the team are aware if insulin pricing in Brazil and have an acceptable price target it should be a formality unless the plan is to charge too much of a premium in comparison to other available insulins. It is a registration process. Not a drug approval.
|
|
|
Post by prcgorman2 on Jun 5, 2019 13:00:19 GMT -5
You bring up points I am curious about BarnStormer. Is Afrezza more expensive than RAA to make and what is the discussion on the pricing topic likely to look/sound like with Brazilian regulatory officials?
MNKD: We think a fair price for Afrezza is X.
Brazilian Regulator: That's too high. (Because haggling over price is their job.)
|
|
|
Post by mytakeonit on Jun 5, 2019 15:20:49 GMT -5
Oh No .. just got back from Japan and plan to buy more shares in the morning ... current pps is what I had expected, as previously stated. Will place a low ball order, but will adjust if things don't go my way. Will be great if we all could meet in the future. (Hey sports ... my future wife!!! I'm talking to you !!!) But, that's mytakeonit “Have tent will follow”😁🌴 it’s getting really hot out here in California😎 Yes sports ... I'm pretty excited about the idea also. Oh, that's not what you meant. Ha! It was pretty hot in Hokkaido Japan also. Global warming is heating up. But, that's mytakeonit
|
|
|
Post by mnkdfann on Jun 5, 2019 22:30:09 GMT -5
riotimesonline.com/brazil-news/brazil/anvisa-approves-first-inhaled-insulin-in-brazil/[More at the link.] According to experts, although it represents an alternative for treating diabetes and a benefit in quality of life by reducing the number of injections, Afrezza has limitations. It is unable to replace all daily insulin applications, it has a limited range of dosage and is unsuitable for patients with lung conditions and those under eighteen years of age. On the other hand, it is easier to carry and store as it does not require refrigeration and may reduce the number of needle pricks that the patient has to undergo daily. Inhaled insulin may only replace fast-acting or ultra-fast insulin applications, also called “bolus”. This type of insulin is typically used before each meal when the body needs a larger amount to compensate for sugar intake. The other type of insulin, “basal”, of slower action, is generally used only once daily and cannot be replaced by the inhaled drug, as explained by Lívia Porto, an endocrinologist at the Centro Especializado em Obesidade e Diabetes of Hospital Alemão Oswaldo Cruz, which specializes in treating obesity and diabetes. “If a diabetic patient is treated using this basal-bolus therapy, he or she typically takes at least four injections a day: one basal and three boluses, for breakfast, lunch, and dinner. Switching to an inhaler would reduce it from four daily doses to one. It would be a gain in quality of life, although it would not entirely replace the injection”, says the doctor. For Heraldo Marchezini, CEO of Biomm, the company responsible for product distribution in Brazil, Afrezza’s ease of handling and use represents an improvement in the quality of life of patients. “At mealtimes, the patient often needs to use insulin in a social environment outside the home. The inhalable solution can be faster and more discreet. The inhaler fits in the palm of your hand. It’s a great innovation in terms of use,” he says. He asserts that the product is suitable for type 1 and 2 diabetes patients. Nevertheless, considering that most type 2 diabetics are treated with pills and not with insulin, the main beneficiaries of the new product would be type 1 diabetic patients, who must obligatorily be treated with insulin. “In the case of type 2 diabetics, Afrezza would be recommended only for patients who are unable to control blood glucose by only using oral medication,” explains endocrinologist Freddy Eliaschewitz, scientific advisor to the Brazilian Society of Diabetes and director of the Clinical Research Center CPclin, a Brazilian institution that participated in studies on inhaled insulin. According to the specialist, of the approximately 15 million Brazilians suffering from diabetes, it is estimated that 10 percent suffer from type 1 diabetes and 90 percent from type 2.
|
|
|
Post by buyitonsale on Jun 5, 2019 23:25:50 GMT -5
10% - 1.5 million T1D in Brazil ! I reiterate my 5% market share for Afrezza
|
|
|
Post by seanismorris on Jun 5, 2019 23:46:56 GMT -5
10% - 1.5 million T1D in Brazil ! I reiterate my 5% market share for Afrezza I hope so, but without pricing information, predictions are premature. There are no guarantees Afrezza with be competitive or have enough resources will be allocated to train docs.
|
|
|
Post by mnkdfann on Jun 5, 2019 23:57:15 GMT -5
10% - 1.5 million T1D in Brazil ! I reiterate my 5% market share for Afrezza I hope so, but without pricing information, predictions are premature. There are no guarantees Afrezza with be competitive or have enough resources will be allocated to train docs. There are also the statements: "In the case of type 2 diabetics, Afrezza would be recommended only for patients who are unable to control blood glucose by only using oral medication" and "most type 2 diabetics are treated with pills and not with insulin" to be taken into account.
|
|